247 related articles for article (PubMed ID: 19700947)
1. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.
Wang LY; Shofer JB; Rohde K; Hart KL; Hoff DJ; McFall YH; Raskind MA; Peskind ER
Am J Geriatr Psychiatry; 2009 Sep; 17(9):744-51. PubMed ID: 19700947
[TBL] [Abstract][Full Text] [Related]
2. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study.
Peskind ER; Tsuang DW; Bonner LT; Pascualy M; Riekse RG; Snowden MB; Thomas R; Raskind MA
Alzheimer Dis Assoc Disord; 2005; 19(1):23-8. PubMed ID: 15764868
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
4. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
[TBL] [Abstract][Full Text] [Related]
5. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
6. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Herrmann N; Gauthier S; Boneva N; Lemming OM;
Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
[TBL] [Abstract][Full Text] [Related]
8. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings JL; Schneider E; Tariot PN; Graham SM;
Neurology; 2006 Jul; 67(1):57-63. PubMed ID: 16832078
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
Tariot PN; Erb R; Podgorski CA; Cox C; Patel S; Jakimovich L; Irvine C
Am J Psychiatry; 1998 Jan; 155(1):54-61. PubMed ID: 9433339
[TBL] [Abstract][Full Text] [Related]
10. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
Tariot PN; Raman R; Jakimovich L; Schneider L; Porsteinsson A; Thomas R; Mintzer J; Brenner R; Schafer K; Thal L; ;
Am J Geriatr Psychiatry; 2005 Nov; 13(11):942-9. PubMed ID: 16286437
[TBL] [Abstract][Full Text] [Related]
11. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Street JS; Clark WS; Gannon KS; Cummings JL; Bymaster FP; Tamura RN; Mitan SJ; Kadam DL; Sanger TM; Feldman PD; Tollefson GD; Breier A
Arch Gen Psychiatry; 2000 Oct; 57(10):968-76. PubMed ID: 11015815
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
[TBL] [Abstract][Full Text] [Related]
16. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
[TBL] [Abstract][Full Text] [Related]
17. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
[TBL] [Abstract][Full Text] [Related]
19. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
[TBL] [Abstract][Full Text] [Related]
20. Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients.
Herrmann N; Lanctôt KL; Eryavec G; Khan LR
J Psychopharmacol; 2004 Jun; 18(2):215-20. PubMed ID: 15260910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]